In January 2025, Medra used an update on its medical dictionary, which was used to report side effects. This update introduces terminological reforms aimed to increase the global pharmacy system. The new vocabulary is designed to better capture and classify side effects, providing more accurate and detailed data that will help regulators and pharmaceutical companies explore and evaluate security signals more efficiently.
In February 2025, the Veva Systems Integrated Artificial Intelligence (AI) and Machine Learning (ML) were in the pharmaclance processes. These technologies focus on handling drug safety by analyzing real data and patient results. The use of AI and ML aims to increase the efficiency of the safety assessment, which can quickly identify potential safety problems. By taking advantage of AI's ability to analyze large datasets, tissue pharmaceutical companies help to improve their drug safety operations and create data - that prefer welfare on the patient.
In February 2024, Accenture took its pharmacovigilance prize at the next level by involving advanced AI and automation technologies in the security work. This development focuses on improving the effectiveness of drug safety data analysis and reporting, so that pharmaceutical companies can handle complex security profiles. Integration of automation technologies helps to streamline the Fero administration process, leading to a rapid response to new security problems and improves the general efficiency of safety monitoring efforts.
In June 2024, Parexel expanded its outsourcing services in powerful pharmacovigilans by developing new platforms designed to manage large -scale security monitoring. This expansion allows the company to support the drug and bioform companies with more efficient and comprehensive medical security management. The new platforms are designed to handle the increasing complexity and volume of security data, so that companies can better monitor and assess the side effects of their clinical studies and settings after the market.
In September 2024, Charles River Laboratories also expanded its pharmacovigilance services introducing new technologies to automate the detection of potential drug safety signals during clinical trials. The move aims to help customers better manage the security profiles in the drug development's life cycle. By incorporating advanced risk management solutions, Charles River offers pharmaceutical companies to identify and address security problems in the development process.
In September 2023, BSV's BSV is, 'a mobile application designed to simplify the reporting of potential side effects related to the products. This tool helps to streamline the collection of safety data by making it easy to report side effects for health professionals and patients. By offering a more user -friendly reporting mechanism, BSV aims to increase pharmacovian efforts and ensure that any security problems are immediately detected and addressed.
Impact of Recent developments in Pharmacovigilance Industry
The update to MedDRA’s medical dictionary introduces more precise and accurate terminology for adverse event reporting. This enhances the ability to capture side effects and classify them more efficiently, improving the overall quality of safety data collected globally.
The integration of AI and ML into pharmacovigilance processes allows pharmaceutical companies to analyze real-world data and patient outcomes more efficiently. This enables proactive identification of potential safety problems before they escalate, improving drug safety management.
Accenture’s use of advanced AI and automation technologies enhances the effectiveness of drug safety data analysis, making it easier for pharmaceutical companies to manage complex safety profiles and meet regulatory requirements. AI helps identify potential issues more quickly and accurately, while automation streamlines the reporting process, enabling faster responses to emerging safety concerns. Accenture's technologies help pharmaceutical companies comply with these diverse regulatory frameworks by ensuring timely and accurate reporting of adverse events, aligning with global standards set by agencies like the FDA, EMA, and WHO. By integrating AI and automation, companies can more efficiently meet regulatory obligations, reduce the risk of non-compliance, and ultimately ensure the safety of their products across different markets worldwide.
Parexel’s new platforms for large-scale safety monitoring provide pharmaceutical companies with a more scalable and comprehensive solution for tracking adverse events across clinical trials and post-market settings, ensuring drug safety. This helps companies handle the increasing complexity and volume of safety data more effectively. By utilizing these advanced platforms, pharmaceutical companies can proactively detect, evaluate, and manage adverse events, ensuring that potential risks are identified and addressed promptly. This continuous monitoring helps safeguard public health, reduces the risk of harm to patients, and ensures that drugs remain safe and effective both during clinical development and once they are on the market.
Charles River Laboratories' introduction of new technologies to automate the detection of safety signals during clinical trials is revolutionizing the efficiency of safety monitoring through the use of Artificial Intelligence. This helps clients identify potential drug safety issues earlier in the drug development lifecycle, reducing the likelihood of safety concerns emerging after the product reaches the market. AI-driven algorithms can sift through vast amounts of clinical trial data, patient reports, and real-world evidence, detecting patterns that may indicate safety issues. This revolutionizes the ability to identify risks early and accurately, allowing for more proactive decision-making in both clinical trials and post-market monitoring, ultimately improving patient safety and reducing the time and cost associated with addressing safety concerns.
According to Coherent Market Insights (CMI), the global Pharmacovigilance Industry size is set to reach US$14.3 billion in 2032. Global Pharmacovigilance Industry will likely increase at a CAGR of 8.3% during the forecast period.
The launch of the BSV AER mobile application simplifies the process of reporting adverse events. By providing a user-friendly interface, the app encourages healthcare professionals and patients to report potential side effects more easily, leading to more comprehensive and accurate safety data collection.
Source:
News Outlet: Cable News Network, The Guardian, U.S News and World Report
